Pharma Tech Outlook: Pharma Tech Magazine


Top 10 Drug Discovery and Development Solution Companies in Europe - 2019


In the pharmaceutical industry, the process of developing nascent drugs to cure a disease is quite long, costly, and at the same time uncertain. In light of this, many experts in this space cite that the costs of developing new drugs can be reduced by the use of new technologies and with a deep understanding of biology. Albeit the objectives of drug delivery remain the same, the methods and techniques used in drug development continue to experience radical changes. In a nutshell, the standard approach to drug discovery is to identify a single molecular disease target and subsequently identify a compound that interacts and modulates with high specificity. Today, majority of the innovation reinvigorating the drug development methodologies seeks to access and integrate more information – about targets, compounds, and disease phenotypes. Next, the increasing size of chemical libraries and high throughput screening (HTS) technologies have enabled thousands or millions of compounds to be screened and the concomitant increase in compounds have supplemented the urgency for the bioanalysis of metabolites, and a need for faster turnaround.

To assist CIOs maneuver in the right direction while working on Drug Discovery and Development, a distinguished panel of CEOs, CIOs, VCs, and analysts along with the Pharma Tech Outlook’s editorial board has selected the leading Drug Discovery and Development service providers in Europe. The companies featured in this edition demonstrate an ability to develop innovative technologies combined with outstanding customer service.

We present to you Top 10 Drug Discovery and Development Solution Providers in Europe - 2019

    Top Drug Discovery and Development Solution Companies in Europe

  • A global metabolomics CRO and manufacturer of capillary electrophoresis-mass spectrometry (CE-MS)-based metabolome analysis

  • Provides a formulation technology platform for the increased stability and improved protection of biopharmaceuticals

  • The biopharmaceutical company discovers highly selective novel small molecule medicines for a variety of targets and diseases for further development at partners

  • Provides an open, innovative setting for the automation of extensive cellular and biochemical in-vitro screening experiments and High Throughput Screening (HTS) service

  • Provides innovative products and services to enable pharma companies optimize and accelerate their drug discovery processes

  • BC Platforms

    BC Platforms

    Provides powerful genomic data management and analysis solutions that leverage the convergence of genomics and healthcare information technologies

  • Evotech


    Drug discovery and development solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements. The Company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, pain, metabolic diseases, oncology, respiratory diseases, fibrosis, inflammation and infectious diseases. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, Roche and UCB



    GENFIT is a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. Its most advanced drug candidate, elafibranor, is currently evaluated in pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a potential treatment for nonalcoholic steatohepatitis, or NASH. NASH is considered by regulatory authorities as a medical emergency because of its potentially severe consequences, although often asymptomatic until late stages, and because its prevalence is on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis (PBC), a severe chronic liver disease

  • InSphero


    InSphero provides advanced, easy-to-use 3D tissue-based assay solutions for predictive compound classification to clients in the pharmaceutical, biotech, cosmetics, and chemical/environmental industries. The company is dedicated to creating a healthier society by enabling life science companies to invent safer, novel compounds faster and more efficiently, without the use of laboratory animals. InSphero assay-ready microtissues are engineered and certified for use in critical drug development applications, and validated to ensure uniform size, robust functionality, and reproducible results. The company develops 3D InSight™ Microtissues using the most advanced 3D cell culture technologies available to produce highly predictive, fully QC’d organotypic in vitro models ready to use in pharma drug discovery, efficacy and safety

  • Micronit


    The company’s unique combination of micro- and nanotechnologies, different materials, microfluidics and MEMS knowledge and customer application knowhow, enables them to provide their customers with the innovative and sustainable solution they are looking for. Micronit offers design, development, prototyping, and (contract) manufacturing of ISO 9001 and ISO 13485 lab-on-chip and MEMS solutions. The company is also indulged in consultative partnership focused on making its customers successful. At the core of Micronit is quality manufacturing, creative product development, and researching products and providing custom prototyping services